2023 - Research.com Biology and Biochemistry in Sweden Leader Award
Vladimir Tolmachev focuses on Affibody molecule, Cancer research, Molecular imaging, Biodistribution and Pathology. His Affibody molecule study combines topics from a wide range of disciplines, such as Molecular biology, Phage display and Peptide synthesis. The study incorporates disciplines such as Nuclear medicine, Antibody, Monoclonal antibody and Trastuzumab in addition to Cancer research.
His Molecular imaging study also includes
Vladimir Tolmachev mainly investigates Affibody molecule, Biodistribution, Cancer research, Molecular imaging and In vitro. The subject of his Affibody molecule research is within the realm of Biochemistry. Vladimir Tolmachev usually deals with Biodistribution and limits it to topics linked to Biophysics and Molecule and Stereochemistry.
His work in Cancer research addresses issues such as Monoclonal antibody, which are connected to fields such as Antigen. His Molecular imaging research incorporates themes from Cancer and Breast cancer. The concepts of his In vitro study are interwoven with issues in Molecular biology and Internalization.
The scientist’s investigation covers issues in Biodistribution, Cancer research, Molecular imaging, In vitro and Affibody molecule. His Biodistribution study incorporates themes from Cancer cell, Biophysics, Internalization and Pharmacology, Binding selectivity. Vladimir Tolmachev combines subjects such as Molecular medicine, Targeted therapy, DARPin, Prostate cancer and Monoclonal antibody with his study of Cancer research.
His Molecular imaging research is multidisciplinary, incorporating perspectives in Pet imaging, Breast cancer, Spect imaging and Molecular targets. The various areas that Vladimir Tolmachev examines in his Affibody molecule study include Contrast, DOTA, Magnetic resonance imaging, Cytotoxic T cell and Receptor expression. The DOTA study combines topics in areas such as Molecular biology and Receptor–ligand kinetics.
Vladimir Tolmachev mostly deals with Biodistribution, Molecular imaging, Cancer research, Biophysics and Scaffold protein. His Biodistribution research entails a greater understanding of In vitro. His study on Molecular imaging also encompasses disciplines like
His research investigates the connection between Cancer research and topics such as Prostate cancer that intersect with problems in Peptide synthesis, Peptide and Receptor. His research in Biophysics intersects with topics in Chelation and Affibody molecule. His research investigates the connection between Affibody molecule and topics such as Trimer that intersect with issues in Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
John Löfblom;Joachim Feldwisch;Vladimir Tolmachev;Jörgen Carlsson.
FEBS Letters (2010)
Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
Anna Orlova;Mikaela Magnusson;Tove L.J. Eriksson;Martin Nilsson.
Cancer Research (2006)
Selection and characterization of HER2/neu-binding affibody ligands.
Maria Wikman;Ann-Charlott Steffen;Elin Gunneriusson;Vladimir Tolmachev.
Protein Engineering Design & Selection (2004)
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Richard P. Baum;Vikas Prasad;Dirk Müller;Christiane Schuchardt.
The Journal of Nuclear Medicine (2010)
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
Vladimir Tolmachev;Anna Orlova;Rikard Pehrson;Joakim Galli.
Cancer Research (2007)
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
Anna Orlova;Vladimir Tolmachev;Rikard Pehrson;Malin Lindborg.
Cancer Research (2007)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sörensen;Dan Sandberg;Mattias Sandström;Anders Wennborg.
The Journal of Nuclear Medicine (2014)
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding Affibody molecule
Mikaela Friedman;Anna Orlova;Eva Johansson;Tove L. J. Eriksson.
Journal of Molecular Biology (2008)
Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain
Jan Terje Andersen;Rikard Pehrson;Vladimir Tolmachev;Muluneh Bekele Daba.
Journal of Biological Chemistry (2011)
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualisation of EGFR expression in malignant tumours
Irina Velikyan;Åsa Liljegren Sundberg;Örjan Lindhe;A Urban Höglund.
The Journal of Nuclear Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: